Epstein-Barr virus (EBV) infects most of the world's population and is causally associated with several human cancers, but little is known about how EBV genetic variations might influence EBV-associated diseases and their geographical patterns. In the present study, 22 EBV whole-genome sequences from diseased and healthy individuals were analysed to explore EBV sequence variations at the whole-genome level. We found that the 22 EBV genomes were generally highly similar to each other at the genome level. However, varying degrees of genetic diversity were detected across the entire genome, especially in the latent genes. In contrast, the sequences of promoters and non-coding RNAs were strictly conserved. These findings suggested that both latent genes and non-coding RNAs play important roles in the EBV life cycle. When we investigated changes in known T-cell epitopes in some latent and lytic proteins, we observed that some T-cell epitopes were changed, while others were conserved. These findings indicate that the effect of EBV variations in protein sequences that seem to have been selected by the host immune system should be considered when conducting EBV-targeted immunotherapy. Taken together, our results provide a global view of EBV genome sequence variation, which not only is important for designing vaccines and immunotherapy for EBV but also adds to the understanding of EBV biology and the relationships between viral sequence variation and EBV-associated diseases.
INTRODUCTION
Epstein-Barr virus (EBV) is a ubiquitous gamma-herpesvirus that infects over 90 % of adults worldwide. It is classified into types 1 and 2, based on sequence variation in the EBV nuclear antigen (EBNA)-2 and EBNA-3 genes. Type 1 EBV strains are more prevalent and have a greater cell-immortalizing capacity than type 2 EBV strains [1] . EBV is associated with both non-malignant diseases, such as infectious mononucleosis and multiple sclerosis, and malignant diseases, such as Burkitt lymphoma (BL), Hodgkin lymphoma, some entities of B-and T-cell lymphomas, nasopharyngeal carcinoma (NPC) and a subset of gastric carcinoma [2] . The prevalence of some diseases varies with geography. For example, the incidence of multiple sclerosis is greater in higher latitudes in Caucasian populations than it is in the tropics. NPC is much more prevalent in Asia, while BL is found most commonly in equatorial Africa [3] .
The EBV life cycle consists of two broadly distinct stages: the latency stage, in which only a subset of viral genes are expressed, and the viral replication stage (lytic reactivation), in which infectious virus particles are produced. The limited viral gene products expressed during latency comprise six nuclear proteins (EBNA-1, -2, -3A, -3B, -3C and -LP), three latent membrane proteins (LMP-1, -2A and -2B), two EBVencoded small non-coding RNAs (EBER1 and -2) and the BamHI A rightward transcripts (BARTs) [4, 5] . While EBNA-1, LMP-1 and -2A are critical, EBNA-2, -3A, -3C and -LP are individually essential for the in vitro transformation of primary B cells to lymphoblastoid cell lines (LCLs) [6] . EBERs contribute to cell growth and resistance to apoptosis [7] . During the lytic phase, approximately 80 proteins are expressed, including various immediate early, early and late proteins, which can be further classified based on function into capsid, glycoprotein (such as BLLF-1 and BALF-4), tegument (such as BPLF-1), nucleotide metabolism, packaging, replication and signalling proteins, transcription factors (such as BZLF-1) and proteins of unknown function [2, 4, 8] . The glycoproteins BLLF-1 and BALF-4 are required for viral binding to receptors and interacting with other glycoproteins to trigger virus-cell membrane fusion when the virus enters the cell [9] . The tegument protein BPLF-1 contributes to innate immune evasion by interfering with Toll-like receptor (TLR) signalling [10] . The transcription factor BZLF-1, also known as Zencoded broadly reactive activator, is a trans-activator that can switch EBV from a latent to a lytic phase [11] .
In addition to EBERs, EBV produces other non-coding RNAs (ncRNAs), including viral microRNAs (ebv-miRNAs), an internal ribosomal entry site in the EBNA-1 mRNA (IRES_EBNA-1) and two Epstein-Barr virus stable intronic-sequence RNAs (ebv-sisRNAs). Ebv-miRNAs play important roles in the regulation of both viral and host gene expression. For example, BART miRNAs target caspase 3, p53-upregulated modulator of apoptosis and Bim, which would inhibit apoptosis [12] [13] [14] . IRES_EBNA-1, which is a known structured RNA with functional importance, is capable of stimulating cap-independent translation of EBNA-1. ebv-sisRNA-1 and ebv-sisRNA-2, which are transcribed from the W repeats during latency III, are newly identified ncRNAs that might play a role in the maintenance of latency in EBV [15] .
Why EBV is associated with different malignancies in different geographic regions remains puzzling and may be related to EBV genotypic variability through specific disease and geographic associations. A number of studies have focused on genotyping the polymorphic regions in the EBV genome, such as LMP-1, EBNA-1 and BZLF-1, among others [16] [17] [18] [19] . LMP-1 deletions and point mutations have been suggested to be associated with lymphoproliferative diseases [20] . The prevalence of a 30 bp deletion in LMP-1 was higher in individuals with NPC than in healthy individuals in China [3] . The frequent association of the LMP-1 deletion variant Asp335 with NPC in Hong Kong has also been reported [21] . A specific EBNA-1 subtype (V-val) was detected in diseased and healthy samples exclusively in Asia, while the V-leu subtype showed preferential occurrence in African and South American patients with BL [16, 22, 23] . The studies conducted to date have focused on different regions of EBV in different geographical areas with different disease status, making comparisons across studies difficult and limiting our ability to define the full spectrum of diversity within the EBV genome. Thus, it seems that conducting a genome-wide comparison of EBV genomes would be beneficial. A more comprehensive exploration of EBV diversity across its entire genome might allow us to understand virus transmission patterns, virus phenotypes and disease-associated genotypes. In addition, this type of analysis is important for the design of an EBV vaccine and/ or immunotherapy for EBV. EBV-encoded proteins such as EBNA-2, EBNA-3, LMP-1 and LMP-2A harbour antigenic epitopes of cytotoxic T-lymphocytes (CTLs) [24, 25] . Thus, these proteins could act as potential targets for an EBVspecific CTL-based therapy for EBV-associated diseases [25] [26] [27] . Moreover, a genome-wide comparison could also add to the understanding of the potential regulatory properties of gene expression by analysing variations in promoter elements and ncRNAs.
The first complete EBV genome sequence, B95-8, which was derived from an American patient with infectious mononucleosis, was published in 1984 [28] . Since then, 21 additional EBV whole-genome sequences have been reported piecemeal, including AG876, Akata, C666-1, GD1, GD2, HKNPC1-9, K4413-Mi, K4123-Mi, Mutu, NA12878, NA19114, NA19315 and NA19384 [29] [30] [31] [32] [33] [34] [35] [36] [37] . More recently, Palser et al. [38] sequenced 71 new EBV sequences, most of which were from spontaneous LCLs from Australia and Kenya.
Here, we have described a genome-wide comparison of the 22 previously scattered published EBV sequences from diseased and healthy individuals. We analysed the sequence variations in the 22 EBV strains by comparative and phylogenetic analyses. We also investigated mutations in the promoter sequences Cp, Qp, Fp, LMP1p and LMP2Ap, variations in ncRNAs and changes in CD4 + and CD8 + epitopes in some latent and lytic proteins that may alter CD4 + and CD8 + T-cell recognition.
RESULTS
Global comparison of the 21 EBV genomes to the reference EBV genome A pairwise alignment of the 21 EBV genomic sequences with the reference EBV genomic sequence was performed, and the comparison results are displayed in Fig. 1 . This analysis showed that the EBV genomes generally have high sequence identity, except for repeat regions and polymorphic regions spanning EBNA-2, -3A, -3B and -3C. In particular, AG876, the only type 2 EBV strain in the present study, showed lower identity in EBNA-2, -3A, -3B and -3C than the type 1 EBV strains. The overall sequence similarities between the 21 EBV genomes and the reference EBV genome were high, ranging from 97.45 to 99.74 % (Table S1 , available in the online Supplementary Material).
Phylogenetic analysis of the 22 EBV genomic sequences A phylogenetic analysis based on the whole-genome alignment of the 22 EBV genomes revealed that K4123-Mi, K4413-Mi, Mutu, NA12878, NA19114, NA19315 and NA19384 were more closely related to the reference EBV genome. These nonAsian genomes were more different from EBV genomes derived from Asia. AG876, the only type 2 EBV strain included in the analysis, was the most distant sequence among all the EBV sequences (Fig. 2) . In the phylogenetic analyses based on EBNA-2, -3A, -3B and -3C, AG876 was more obviously distant from the other EBV sequences, which are all type 1 EBV strains (Fig. S1 ). Phylogenetic analyses based on the type-independent genes, EBNA-1, LMP-1, LMP-2A, LMP-2B, BLLF-1, BPLF-1 and BZLF1, showed that the EBV sequences generally clustered in a manner consistent with Fig. 1 . Pairwise alignment of the 21 EBV genomic sequences with the reference EBV genome. The 21 EBV genomes examined generally had high sequence identity with the reference EBV genome, except for the sequences in the OriP repeat region and polymorphic genes, such as EBNA-2 and -3. In particular, the EBNA-2 and -3 genes showed lower sequence identity in AG876 (type 2) than in other EBV sequences (type 1). The figure was generated by mVISTA software, using a 100 bp moving window with a minimum identity of 50 % and a maximum identity of 100 %. Repeat regions are shown in light green, while latent genes are shown in blue. K stands for multiples of 1000. The values on the x-axis represent the nuclotide position in the EBV genome. IR, internal repeat; TR, terminal repeat. geographical locations. Specifically, in phylogenetic analyses based on EBNA-1, LMP-1 and LMP-2A, all Asian-derived EBV strains, including Akata, C666-1, GD1, GD2 and HKNPC1-9, formed a clade that is distant to the non-Asian strains, B95-8/Raji, AG876, K4413-Mi, K4123-Mi, Mutu, NA12878, NA19114, NA19315 and NA19384 (Fig. S1 ). The phylogenetic tree based on LMP-2B showed that GD1 was more closely related to Akata, NA19384 and K4123-Mi, while the rest of the NPC-derived EBV sequences clustered in another branch. An analysis of the nucleotide sequences of BLLF-1 and BPLF-1 (Fig. S1) showed that all of the Chinese viruses, except GD1, HKNPC6 and HKNPC7, were closely related. Specially, in the phylogenetic tree based on the BZLF-1 gene, AG876 clustered with the Asian-derived EBV genomes (Fig. S1 ).
Identification of single nucleotide polymorphisms and indels in EBV genomes
The variations, including single nucleotide polymorphisms (SNPs) and insertions and deletions (indels) of each pairwise comparison of the 21 EBV sequences against the reference EBV sequence, are shown in Table S2 . Consistent with the global comparison results, the overall mutation rates of the 21 EBV genomes were low. To explore the possible association of the EBV variations with disease status, we sorted out the SNPs and indels that were shared in NPC-derived or BL-derived EBV strains. The C666-1, GD1, GD2 and HKNPC1-9 isolates, which are all derived from patients with NPC, shared 562 SNPs when compared to the reference EBV genome; 426 of these SNPs were located in coding regions (Table 1 and Fig. S3 ). The largest proportion of shared SNPs is located in LMP-1 (45/ 426), followed by BPLF1 (22/426) and BRRF2 (22/426) (Table S3 ). According to the function of EBV-encoded proteins, a large proportion of these shared SNPs in coding regions were located in latent (95/426) and tegument (71/ 426) proteins, followed by glycoproteins (58/426). The remaining SNPs were situated in genes encoding proteins involved in replication, packaging and transcription, capsid proteins and proteins of unknown function (Fig. 3a) . When focusing on the viral genomes derived from patients with BL (AG876, Akata and Mutu), we found that these three genomes shared 334 SNPs, 235 of which were located in coding regions (Table 1 , Fig. S4 ). The EBNA-LP gene had the highest number (52/235) of mutations, followed by LMP-2 (22/235) (Table S4) . A large proportion of the shared SNPs in the coding regions of the BL-derived strains were located in latent proteins (102/235), followed by tegument proteins (33/235) (Fig. 3b) . Interestingly, when we analysed the variations shared by the EBV strains derived from healthy individuals, we found that the four EBV genomes from the 1000 Genomes Project shared only one non-synonymous SNP, which was located in BRLF1. When we added K4413-Mi and K4123-Mi to this analysis, there were no common SNPs (Fig. S5) .
We also analysed EBV variations based on geographic regions. As the majority of EBV genomes were from Asia and Africa, and limited data were available from other geographic regions, we analysed the variations in EBV strains from Asia and Africa. The Asian-derived sequences, Akata, C666-1, GD1, GD2 and HKNPC1-9, shared 537 SNPs when compared with the reference EBV genome (Table 1 and Fig. S6 ), 405 of which were located in coding regions. The largest proportion of these SNPs were located in LMP-1 (39/405), followed by LMP-2 (23/405), BPLF1 (22/405) and BRRF2 (22/405) (Table S5) . A large proportion of the coding-region SNPs shared by the Asian EBV strains were located in latent proteins (90/405), followed by tegument proteins (73/405) (Fig. 3c) . NA19114, NA19315, NA19384, AG876 and Mutu are African virus strains. They shared 111 SNPs and 2 indels when compared with the reference EBV genome, 35 of which were non-synonymous SNPs (Table 1, Fig. S7 ). The BBLF4 (10/87) and LMP-2 (10/87) genes had the largest share of SNPs located in coding regions, followed by EBNA-1 (9/87) ( Table S6) . A large proportion of the coding-region SNPs shared by African-derived strains were located in latent proteins (26/87) and replication proteins (15/87), followed by tegument proteins (13/87) (Fig. 3d ).
In addition, we performed a comparative whole-genome SNP analysis of EBV strains to investigate the potential origin and the history of the global spread of EBV. The wholegenome-based SNP phylogenetic analysis revealed that the isolates segregated into several clades, with the strains collected from Asia forming a clade and AG876 forming a distinct clade, while the other non-Asian strains formed another clade (Fig. S1l) .
Amino acid changes in CD4
+ and CD8 + T-cell epitopes of the EBNA-1, -2, -3A, -3B, -3C, LMP-1, -2, BLLF-1 and BZLF-1 proteins The amino acid variations in CD4 + and CD8 + T-cell epitopes of EBNA-1, -2, -3A, -3B, -3C, LMP-1, -2, BLLF-1 and BZLF-1 among EBV genomes are summarized in Table S7 . Because some nucleotide changes may lead to the truncation of translated proteins or a much different sequence from the original, we only included the sequences that had amino acid annotations in the National Center of Biotechnology Information website. We found that some epitopes were conserved among EBV genomes, while some were changed. In total, for CD4 + epitopes, amino acid changes were found in fifteen (15/16) Variations in promoter sequences: Cp, Qp, Fp,
LMP1p and LMP2Ap
In the present study, we observed the variations in the Cp, Qp, Fp, LMP1p and LMP2Ap sequences in the 22 EBV genomes. Wp sequence variations could not be observed because it is located in the 3 kb major internal repeat, whose sequences have not been clearly determined. When compared to the reference EBV genome, Cp had 36 point mutations and 3 indels in its 808 nucleotides, 6 point mutations of which were shared by the Asian-derived sequences (coordinates 10 624 G>T, 10 739 T>C, 10 815 G>T, 10 854 A>C, 10 919 C>T and 11 338 G>T). In addition, GD2 had a 13 bp insertion that was not found in other sequences. 
Variations in ncRNAs
In addition to coding RNAs, which can be translated into proteins, EBV produces ncRNAs, including EBER1 and EBER2, ebv-miRNAs, IRES_EBNA-1 and two ebv-sisRNAs. We analysed the sequence variations of these ncRNAs in the 22 EBV sequences and found that all ncRNAs were generally highly conserved (Table S8 ). The average pairwise sequence identity (APSI) of these ncRNAs ranged from 91.35 to 100 %.
Specifically, EBER1 did not contain any mutations, while EBER2 contained six mutations, five of which (6999 T>G, 7001 A>T, 7012 A>G, 7016 A>T and 7048 A>C) were found in all Asian-derived EBV genomes except GD1 and Akata. In addition, a 23 bp deletion was found in the EBER2 sequence of GD2. The APSIs of EBER1 and EBER2 were 100 and 97.15 %, respectively.
For ebv-miRNAs, the APSI ranged from 98.24 to 100 %, indicating that the ebv-miRNAs were conserved in the 22 EBV strains. We found a C-to-T mutation in ebv-miR-BART8, a G-to-A mutation in ebv-miR-BART10, a C-to-G mutation in ebv-miR-BART12, a C-to-T mutation in ebvmiR-BART17, a T-to-C mutation in ebv-miR-BART19 and a G-to-A mutation in ebv-miR-BHRF1-3.
For IRES_EBNA-1, a T-to-C mutation at coordinate 55 296 was found in all sequences except NA12878. In addition, GD2 had an additional 17 bp deletion at coordinate 55 350. The ebv-sisRNA-1 sequence was 100 % conserved, while the APSI of ebv-sisRNA-2 was only 91.35 %.
Unknown (64)
Tegument (71) Latency (95) Capsid (35) Glycoprotein (58) Nucleotide metabolism (19) Packaging (23) Replication (42) Signalling (19) (a) (b)
Unknown (26) Tegument (33) Latency (102) Capsid (4) Glycoprotein (24) Nucleotide metabolism (4) Packaging (8) Replication (28) Signalling (6) Unknown (7) Tegument (13) Latency (26) Capsid (2) Glycoprotein (12) Nucleotide metabolism (5) Packaging (1) Replication (15) Signalling (5) Unknown (63) Tegument (73) Latency (90) Capsid (23) Glycoprotein (55) Nucleotide metabolism (19) Packaging (22) Replication (40) Signalling (20) Fig. 3 . Summary of SNPs in coding regions shared by NPC-derived EBV sequences (a), BL-derived EBV sequences (b), Asian-derived EBV sequences (c) and African-derived EBV sequences (d) based on protein functions. A majority of SNPs were located in latent genes, followed by tegument proteins and glycoproteins.
We found 21 point mutations in ebv-sisRNA-2 sequences, 4 of which (66 C>T, 69 G>T, 337 G>T and 420 C>A) were shared by K4123-Mi, K4413-Mi and Mutu. In addition, a C insertion at position 89 was observed in the ebvsisRNA-2 sequence of K4123-Mi.
DISCUSSION
In the present study, we performed an in-depth comparative analysis of 22 previously scattered reported EBV genomes from diseased and healthy individuals to explore EBV sequence variations at the whole-genome level. We found that the 22 EBV genomes were generally highly similar to each other at the genome level. Specifically, both the global comparison and pairwise alignment of the 21 EBV genomes against the reference EBV genome indicated that the 22 EBV genomes generally have high sequence identity except for several polymorphic regions, such as EBNA-2, -3A, -3B and -3C. In addition, there were also varying degrees of genetic diversity across the entire genome, especially in the latent genes. In contrast to the frequent mutations that occurred in protein-coding EBV sequences, the sequences of promoters and ncRNAs were strictly conserved.
In this study, both the global comparison and the pairwise alignment of the 21 EBV genomes against the reference EBV genome showed that the EBV genomes were generally similar to each other. The overall sequence similarities between the 21 EBV genomes and the reference EBV genome ranged from 97.45 to 99.74 %. Consistent with this finding, we also found that the mutation rates of the 21 EBV genomes were low when compared to the reference EBV genome. The most distinct EBV sequence was AG876, which harboured 2408 SNPs and 139 indels. The mutation rate was only approximately 1.27 %.
Regarding the distribution of the mutations, we found that nucleotide diversity was observed across the entire genome. However, the EBNA-2, -3A, -3B and -3C genes were the major regions that possessed a number of variations. EBV strains have been classified into type 1 and type 2 based primarily on the sequence of their EBNA-2 and EBNA-3 genes [2] . In the present study, AG876, the only type 2 EBV strain, showed lower identity in the EBNA-2, -3A, -3B and -3C sequences than the type 1 EBV strains. For EBNA-2, the identity between type 1 and type 2 strains at the nucleotide level and in the protein sequence is only 53 and 64 %, respectively [39] . The sequences of the EBNA-3A, -3B and -3C genes between type 1 and type 2 strains differ by 10, 12 and 19 % at the base pair level [40] . In the phylogenetic analyses based on EBNA-2, -3A, -3B and -3C, AG876 was obviously quite distant from the other EBV sequences, which are all type 1 EBV strains. Taken together, these findings suggested that the EBNA-2, -3A, -3B and -3C genes differ a lot between type 1 and type 2 EBV sequences. A principal component analysis conducted by Palser et al. [38] also suggested that the type 1/type 2 classification was the major form of variation in EBV genomes and was almost entirely dependent on the EBNA-2 and EBNA-3 genes. Therefore, the well-established type 1/type 2 classification was confirmed at the genome level. It is known that type 1 EBV strains have a greater cell-immortalizing capacity than type 2 EBV strains [1] . Thus, EBNA-2 and EBNA-3 genes may play important roles in transforming B cells into LCLs.
In addition to the EBNA-2 and EBNA-3 genes, other EBVencoded genes also showed nucleotide variations. In the present study, we determined that SNP density varied substantially across all known ORFs and was highest in latencyassociated genes. This finding was consistent with the previous study conducted by Palser et al. [38] . Latent EBV infection has a substantial role in causing many human diseases, especially malignant tumours. The latent proteins are the limited viral-encoded proteins expressed during EBV latency. When EBV co-evolves with a host, under the positive selection imposed by the host, EBV tends to generate variations in order to escape the host immunosurveillance [41, 42] . Thus, it is not surprising that we observed a higher SNP density in latent genes in the present study. In addition, some EBV-encoded latent proteins, such as LMP-1 and LMP-2A, harbour CTL epitopes [24, 25] . Mutations in these CTL epitopes would be expected to affect the CTL response and confer an advantage on EBV for immune escape and virus persistence in tumour cells, thus playing a role in tumorigenesis and tumour maintenance [43] . In the present study, we found that four (4/7) CD8 + epitopes of LMP-1 and fifteen (15/26) CD8 + epitopes of LMP-2 had amino acid changes. These epitope mutations may result in a reduced CTL response and confer complexity to proposed immunotherapeutic approaches for EBV-associated malignancies. Therefore, the effect of epitope variation should be considered when conducting targeted immunotherapy.
In addition to the latent genes, the genes that encode glycoproteins and tegument proteins were also found to harbour variations. For example, non-synonymous mutations in the glycoprotein genes BLLF-1 (79 265 C>G) and BALF-4 (157 568 C>T) were found to be common in NPC-derived genomes. These mutations caused amino acid changes at the CR2 receptor binding site of gp350 (E201Q) and at the furin cleavage site of gB (D433N), respectively [44, 45] . Since gp350 and gB are glycoproteins that are responsible for EBV binding to and entering host cells, these mutations might influence the binding and entering of EBV into host cells. BPLF-1 is a tegument protein that contributes to innate immune evasion by interfering with TLR signalling [10] . Its N-terminal region exhibits deubiquitinating activity, which can remove ubiquitin tags from proteins in the TLR signalling cascade [10] . In the present study, we found that BPLF-1 contained 22 common SNPs in NPC-derived sequences, and there were two non-synonymous mutations in its N-terminal region, which exhibit deubiquitinating activity. Thus, the function of BPLF-1 might be influenced by these mutations.
In contrast to the EBV-encoded genes, the sequences of promoters were highly conserved among EBV genomes. Only a few point mutations were found in the sequences of Cp, Qp, Fp and LMP2Ap. The mutation rates of ncRNAs were even lower. EBER1, ebv-miR-BART2, 3, 4, 5, 14, 16, 20, 22 , ebvmiR-BHRF1-1, -2 and ebv-sisRNA-1 were 100 % conserved among the 22 EBV genomes. In other ncRNA sequences, only scattered mutations could be identified. EBV-generated ncRNAs play important roles in mediating host-virus interactions and in regulating viral processes [15] . For example, ebv-miRNAs are differentially regulated during viral latency in EBV-associated diseases [46] [47] [48] [49] . ebv-miRNAs target a variety of viral and host genes for regulation [50, 51] . Therefore, the conservation of EBV-generated ncRNAs suggests a conserved functional significance in the EBV life cycle.
To investigate the role of EBV genomic variation in EBVassociated diseases, we performed phylogenetic analyses and investigated SNPs and indels in the EBV genomes that were shared by strains derived from healthy individuals, patients with NPC and patients with BL. Interestingly, we found that there was no common SNP shared by the EBV strains derived from healthy individuals. In contrast, however, there were hundreds of mutations that were shared by NPC-derived or BL-derived EBV strains. These findings suggested that there might be some disease-associated variations in the EBV sequence. In support of this, in the present study, we found that some SNPs in the LMP-1 sequence (such as 167 899 C>A, 168 173 A>G, 168 229 G>A and 168 236 T>C, among others) were shared by NPC-derived EBV strains but not by BL-derived EBV strains. These shared SNPs were also detected in most of the EBV sequences derived from patients with NPC, but not detected in EBV sequences derived from patients with BL [19, 52, 53] . In addition, recently, Feng et al. [54] showed that a SNP (155 391 G>A) in the EBV genome was strongly associated with a high risk of NPC. This locus was detected in almost all NPC-derived EBV genomes (except GD1) but not found in any BL-derived EBV genomes in our study. These findings, to some extent, might support the idea that there are some disease-associated variations in the EBV sequence.
When we analysed EBV variations based on geographic region, we found that limited data were available from geographic regions other than Asia and Africa. In addition, most Asian-derived EBV strains were from patients with NPC, while the African-derived EBV strains were from patients with BL and healthy individuals. Therefore, it seems inappropriate to draw any conclusions about the relationship between EBV variations and geography. More whole EBV genomes from different geographic regions are needed to draw a definitive conclusion.
In summary, the present study presents an in-depth comparative genomics study of EBV. The frequent variations occurring in the latent genes suggested that EBV was under positive selection when it co-evolved with hosts. Since some T-cell epitopes in EBV-encoded latent proteins were found to be changed, the effect of EBV variations should be considered when EBV-targeted immunotherapy is conducted. In contrast, the conservation of EBV-encoded ncRNAs and promoter sequences suggested their conserved functional significance in the EBV life cycle.
METHODS EBV genome sequences
The 22 EBV whole-genome sequences in the present study include B95-8/Raji (the reference EBV sequence), AG876 (the only type 2 EBV sequence), Akata, C666-1, GD1, GD2, HKNPC1-9, K4413-Mi, K4123-Mi, Mutu, NA12878, NA19114, NA19315 and NA19384.
The B95-8 strain was derived from an American patient with infectious mononucleosis. It was established by infecting marmoset B cells with EBV from an individual with infectious mononucleosis. M13 subclone libraries were constructed from suitable EcoRI or BamHI fragments of B95-8 EBV by the sonication method using the M13mp8 and M13mp9 vectors. The complete nucleotide sequence was then determined using the dideoxynucleotide procedure [28] . This was shot-gun sequencing. Since the B95-8 EBV sequence has a large fragment deletion (~12 kb), a more complete 171 kb EBV reference genome (accession no. NC_007605) was later constructed using B95-8 as a backbone, while the 12 kb missing fragment in the EBV genome was provided by the EBV sequence found in Raji cells [55] . This is the most widely used EBV sequence.
AG876 originated from an African patient with BL and is the first complete type 2 EBV sequence. The DNA sequence was analysed by constructing cosmid libraries from a Sau3AI digestion, followed by dideoxynucleotide sequencing [29] .
Akata and Mutu were derived from Asian and African BL cell lines, respectively. After using anti-immunoglobulin antibodies to increase the ratio of the viral genome, the researchers performed a de novo assembly of the Akata and Mutu EBV genomes using next-generation sequencing [30] .
The C666-1, GD1, GD2 and HKNPC1-9 genomes were derived from NPC patients. C666-1 is an epithelial cell line derived from an NPC xenograft of southern Chinese origin. The complete genome was constructed by reference mapping [36] . GD1 was sequenced from the saliva of an NPC patient using PCR amplification and subcloning followed by conventional dideoxy-based DNA sequencing [33] . GD2 and HKNPC1-9 were direct isolates from primary NPC biopsy specimens. A small subset of sequencing reads from next-generation sequencing of the total DNA sequences derived from an NPC biopsy specimen were mapped to the EBV reference genome, and the mapped reads were assembled to yield the GD2 genome [34] . HKNPC1 was sequenced using Amplicon Sequencing (PCR enrichment) followed by next-generation (Illumina) and conventional dideoxy-DNA sequencing [35] , while the HKNPC2-9 sequences were established by targeted enrichment of EBV DNA by hybridization, followed by next-generation sequencing, de novo assembly and joining of contigs by Sanger sequencing [37] .
In addition to the above 16 EBV genomes from diseased individuals, six EBV genomes were derived from healthy individuals. The K4413-Mi and K4123-Mi genomes were from two human peripheral blood B lymphocyte lines that underwent spontaneous immortalization promoted by mycoplasma infections in culture. Sequencing reads from the two cell lines were obtained using the high-throughput sequencing Illumina MiSeq platform [31] . The NA12878, NA19114, NA19315 and NA19384 sequences were derived from healthy individuals in the 1000 Genomes Project. By mapping the natural EBV reads to the EBV reference genome, researchers constructed nearly completely wildtype viral genomes from four individuals [31, 32] .
The reference EBV genome sequence (B95-8/Raji, accession no. NC_007605) and 17 EBV genomes (AG876, Akata, C666-1, GD1, GD2, HKNPC1-9, K4413-Mi, K4123-Mi and Mutu) were retrieved from the GenBank database. GenBank files contain annotations and genome sequences. The NA12878 sequence was kindly provided by Professor ShyhChing Lo, and the NA19114, NA19315 and NA19384 sequences were acquired from the supplementary materials from the article 'Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1000 Genomes Project' [32] . The information regarding the 22 EBV genome sequences, including their accession numbers, is summarized in Table 2 .
Comparative and phylogenetic analysis A global comparison and visualization of 21 EBV genome sequences (AG876, Akata, C666-1, GD1, GD2, HKNPC1-9, K4413-Mi, K4123-Mi, Mutu, NA12878, NA19114, NA19315 and NA19384) against the reference EBV genome sequence (B95-8/Raji) was performed using the mVISTA program (http://genome.lbl.gov/vista/mvista/submit.shtml) with a 100 bp moving window. The region (13-42 kb) with highly repetitive sequences in the EBV genome where a majority of gaps and ambiguity reads occurred was not included in the genomic comparison.
The global sequence alignments of the 22 EBV genomes and individual gene sequence alignments were analysed using MUGSY software (version 1.0). The alignments were used to generate phylogenetic trees with a maximum likelihood algorithm.
Identification of variations in the EBV genomic sequences
Lists of SNPs and indels were generated from each pairwise comparison of the 21 EBV sequences against the reference EBV sequence using the LASTZ software (version 1.02.00). The variations identified in the major repeats, including internal repeats 1 to 4, terminal repeats and a family of repeats, were disregarded. Positions without sequence data or those marked with 'N' were also ignored in the mutation analysis. Particular attention was paid to the promoter and coding region of a protein. Those mutations that resulted in amino acid changes in known CD4 + and CD8 + T-cell epitopes [38, 56] were of most interest. In addition, the SNPs and indels that were shared by NPC-derived, BL-derived, healthy-individual-derived, African-derived and Asianderived EBV strains were analysed.
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